SC-236|cas:170569-86-5|西域试剂

SC-236,99.45%

产品编号：Bellancom-W010983| CAS NO：170569-86-5| 分子式：C₁₆H₁₁ClF₃N₃O₂S| 分子量：401.79

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-W010983	￥800.00	杭州北京（现货）
Bellancom-W010983	￥1200.00	杭州北京（现货）
Bellancom-W010983	￥2500.00	杭州北京（现货）
Bellancom-W010983	￥4500.00	杭州北京（现货）
Bellancom-W010983	￥7500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

SC-236

产品介绍

SC-236 是具有口服活性的 COX-2 特异性抑制剂 (对 COX-1 的 IC₅₀ 值为 10 nM)和 PPARγ 激动剂。SC-236 可通过 c-Jun 氨基端抑制激活蛋白-1 (AP-1) 活性。SC-236在小鼠模型中通过抑制 ERK 的磷酸化发挥抗炎作用。

生物活性

SC-236 is an orally active COX-2 specific inhibitor (IC₅₀ = 10 nM) and a PPARγ agonist. SC-236 suppresses activator protein-1 (AP-1) through c-Jun NH2-terminal kinase. SC-236 exerts anti-inflammatory effects by suppressing phosphorylation of ERK in a murine model^[4]^[5].

体外研究

SC-236 (15 μM, 30 min) suppresses the side effects of NSAIDs and prevented inflammation in vECs subjected to ALSS.
SC-236 significantly induces PPARγ expression in HSCs and acted as a potent PPARγ agonist in a luciferase-reporter trans-activation assay.
SC-236 strongly inhibits, in a time- and concentration-dependent manner, macrophage viability.
SC-236, either alone or in combination with 15d-PGJ2, induced a marked pro-apoptotic effect in HSCs in culture.
SC-236 mediates antitumor effect by modulation of AP-1-signaling pathway.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	vECs.
Concentration:	15 μM
Incubation Time:	30 min.
Result:	Showd significant reduction in COX-2 level and increase in IκBα level, thus preventing ALSS-induced NFκB activation and inflammation in vECs.

Western Blot Analysis

Cell Line:	COS 7 cells.
Concentration:	3 and 10 μM.
Incubation Time:	18 h (combined with 15d-PGJ₂).
Result:	Acted in a concentration-dependent manner as a PPARγ agonist.

体内研究
(In Vivo)

SC-236 (6 mg/kg, gavage) exhibits anti-fibrotic properties in CCl4- treated animals.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Seventy-six male adult Wistar rats weighing 200-220 g (CCl₄-treated).
Dosage:	6 mg/kg.
Administration:	Orally, 3 times per week.
Result:	A marked induction of COX-2 protein expression was detected by immunohistochemistry in the liver of CCl4-treated rats. Significantly reduced the degree of liver fibrosis. Dramatically suppressed α-SMA expression in CCl4-treated rats.

体内研究

SC-236 (6 mg/kg, gavage) exhibits anti-fibrotic properties in CCl4- treated animals.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Seventy-six male adult Wistar rats weighing 200-220 g (CCl₄-treated).
Dosage:	6 mg/kg.
Administration:	Orally, 3 times per week.
Result:	A marked induction of COX-2 protein expression was detected by immunohistochemistry in the liver of CCl4-treated rats. Significantly reduced the degree of liver fibrosis. Dramatically suppressed α-SMA expression in CCl4-treated rats.

体内研究

SC-236 (6 mg/kg, gavage) exhibits anti-fibrotic properties in CCl4- treated animals.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Seventy-six male adult Wistar rats weighing 200-220 g (CCl₄-treated).
Dosage:	6 mg/kg.
Administration:	Orally, 3 times per week.
Result:	A marked induction of COX-2 protein expression was detected by immunohistochemistry in the liver of CCl4-treated rats. Significantly reduced the degree of liver fibrosis. Dramatically suppressed α-SMA expression in CCl4-treated rats.

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (248.89 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.4889 mL	12.4443 mL	24.8886 mL
5 mM	0.4978 mL	2.4889 mL	4.9777 mL
10 mM	0.2489 mL	1.2444 mL	2.4889 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (6.22 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (6.22 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (6.22 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (6.22 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (6.22 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (6.22 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。